Ace Therapeutics provides tailored preclinical contract research organization services focused on joint inflammation models for analgesic drug development. Our platform integrates established disease models with comprehensive endpoint assessments to support robust efficacy and safety profiling of novel therapeutics.
Joint inflammation models are critical for evaluating mechanisms of pain and efficacy of analgesic compounds. These models simulate pathological features of human arthritic conditions, facilitating the study of inflammatory mediators, tissue degeneration, and pain pathways. At Ace Therapeutics, we prioritize model relevance and translational validity to enhance preclinical decision-making.
Ace Therapeutics provides end-to-end study execution using various joint inflammation models, including
Model Type | Description | Common Applications |
Collagen-Induced Arthritis (CIA) | Autoimmune, T cell-mediated arthritis induced by collagen II in rodents | Chronic inflammatory arthritis studies |
Adjuvant-Induced Arthritis (AIA) | Inflammation triggered by complete Freund's adjuvant | Acute and subchronic inflammation |
Mono-Iodoacetate (MIA) Model | Chemical cartilage destruction leading to joint degeneration and pain | Osteoarthritis pain research |
Carrageenan-Induced Synovitis | Local acute inflammation in the knee joint | Acute pain and swelling |
Zymosan-Induced Arthritis | Innate immune cell-driven synovial inflammation | Gout and early-stage arthritis studies |
Each model is selected and customized according to the drug's target mechanism, intended indication, and desired endpoints.
Our experienced scientific team collaborates closely with clients to design studies aligned with their objectives. Key assessments include:
All data are generated under strict internal quality processes to ensure reproducibility, transparency, and scientific integrity.
We understand the complexity of translating preclinical findings into human relevance. Therefore, model customization is a key strength of our platform.
Ace Therapeutics is committed to delivering scientifically rigorous and tailored preclinical services to help advance your pain-relief drug discovery pipeline through reliable in vivo joint inflammation modeling.
Can you test our compound in multiple models simultaneously?
Yes. We can run comparative studies across different models (e.g., CIA and MIA) to assess spectrum activity or mechanism specificity.
What types of drugs can be evaluated using these models?
Our models are suitable for a wide range of drug types, including small molecules, peptides, biologics, and natural compounds targeting inflammation or pain.
Can endpoints be customized based on our specific mechanism of action?
Absolutely. We offer flexibility in selecting and designing endpoints such as cytokine expression, histological markers, or behavioral tests tailored to your mechanism.
What types of data will be included in the final report?
The report includes raw data, statistical analysis, graphs, representative images (e.g., histology, imaging), and an interpretative summary by our scientific team.
Make Order
Experimental Scheme
Implementation
Conclusion